🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› EU
Clinical trial register · European Union · CTIS

Recently authorised EU trials

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12445 total CTIS records — a stated recency window, not the full historical archive. Synced 21 Sep 2026, 03:16 UTC
2500
Shown in this register
most recently authorised
12,445
Total on CTIS
full historical archive
745
Phase III
within the shown window
Top member states
Spain 1023 France 890 Germany 861 Italy 742 Poland 587 Netherlands 524
Narrow the registerReset
Phase
Phase I 558 Phase I/II 214 Phase II 726 Phase III 745 Phase IV 257
Lead sponsor
AstraZeneca AB 60 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 45 Novo Nordisk A/S 42 Clear sponsor filter
Member state
Spain 1023 France 890 Germany 861 Italy 742 Poland 587 Netherlands 524 Belgium 426 Czechia 327
All 28 states
42 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase III
Zenagamtide use for the reduction of risk of major adverse cardiovascular events in people with established atherosclerotic cardiovascular disease and either overweight or obesity (AMBIENCE)
2026-525182-53-00Atherosclerotic cardiovascular disease and either overweigh…
Novo Nordisk A/S
Cardiovascular Diseases
Czechia, Greece, France, Italy, Germany, Spain
16/09/2026
Phase I/II
A study assessing the safety, tolerability, pharmacokinetics and efficacy of single and multiple doses of NNC0638-0355 in participants with overweight or obesity
2026-526797-16-00Obesity and overweight
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Netherlands
14/09/2026
Phase I
A research study looking into how a high dose of s.c. semaglutide works with emptying of the stomach in people with excess body weight
2026-526083-20-00Participants with obesity
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Austria
07/09/2026
Phase III
Efficacy and safety of zenagamtide s.c. once weekly compared to insulin glargine s.c. once daily in participants with type 2 diabetes and increased cardiovascular risk inadequately controlled on 1–3 oral glucose-lowering medications (AMBITION 7)
2026-525209-11-00Type 2 diabetes (T2D) and increased cardiovascular (CV) ris…
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Greece, Germany, Italy, Czechia, Poland, Bulgaria, Spain
04/09/2026
Phase I
A research study looking at the effect of timing of meal after dosing and water volume at dosing on how the medicine zenagamtide is taken up by the body of participants with overweight or obesity
2025-521383-35-00overweight/obesity
Novo Nordisk A/S
Not possible to specify
Germany
31/08/2026
Phase II
Efficacy and safety of once-weekly subcutaneous UBT251 in participants with type 2 diabetes – a dose-finding study
2026-525465-42-00Type 2 diabetes (T2D)
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Spain, Hungary, Romania, Slovakia, Poland, Germany
31/08/2026
Phase I
A study to see how safe a new medicine (NNC0705-0002) is in healthy people
2026-526205-15-00Cardiometabolic
Novo Nordisk A/S
Not possible to specify
Netherlands
21/08/2026
Phase I
A research study looking into how a single dose of the medicine NNC0537-1482 moves through the body of participants with normal or reduced kidney function
2026-525271-57-00Heart failure with preserved ejection fraction
Novo Nordisk A/S
Cardiovascular Diseases
Germany
10/08/2026
Phase III
Efficacy and safety of once daily oral semaglutide in adults with overweight or obesity
2025-524626-18-00Overweight and obesity
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Netherlands, Belgium, Greece, Poland, Spain, Denmark, France, Bulgaria, Sweden
10/08/2026
Phase III
A clinical study to compare efficacy and safety of two different doses of CagriSema and semaglutide in participants with obesity with or without type 2 diabetes
2025-522488-14-00Participants with obesity with or without type 2 diabetes
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Greece, Portugal, France, Slovakia, Bulgaria, Netherlands, Romania, Italy, Austria, Poland, Hungary, Spain, Czechia, Belgium
27/07/2026
Phase III
A placebo-controlled comparability study to compare two presentations of cagrilintide for weight management in participants with overweight or obesity
2025-524249-29-00Participants with overweight or obesity
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Sweden, Greece, Hungary, Portugal
20/07/2026
Phase I
A study to see how safe a new medicine (NNC6022-0004) is in healthy people and people living with obesity
2026-525179-26-00Cardiometabolic
Novo Nordisk A/S
Not possible to specify
Netherlands
19/06/2026
Phase III
Efficacy and safety of NNC0487-0111 s.c. once-weekly compared to semaglutide s.c. once-weekly in participants with overweight or obesity, and type 2 diabetes (AMAZE 8)
2024-520446-31-00Participants with overweight or obesity, and type 2 diabetes
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Germany, Croatia, Portugal, Hungary, Bulgaria, Romania, Poland
15/05/2026
Phase I
A research study to see how NNC0487-0111 affects the body’s energy use after a weight loss in adults living with obesity, compared to a low-calorie diet or placebo
2025-522744-40-00Obesity
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Netherlands, Denmark
11/05/2026
Phase III
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with obesity (AMAZE 1)
2024-520440-42-00Obesity
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Denmark, France, Germany, Belgium
04/05/2026
Phase III
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and type 2 diabetes (AMAZE 2)
2024-520441-23-00Overweight or obesity, and type 2 diabetes
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Italy, Croatia, Hungary, Slovakia, Romania
04/05/2026
Phase III
Efficacy, safety and pharmacokinetics of cagrilintide s.c. 2.4 mg as monotherapy and in combination with semaglutide s.c. 2.4 mg (CagriSema) once weekly for weight management in children and adolescents with overweight or obesity
2023-509176-42-00Obesity and T2D
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Slovakia, Austria, Spain, Romania, Portugal, Italy, Denmark, Belgium, Sweden, Poland, Netherlands, Croatia, Hungary, Bulgaria
28/04/2026
Phase III
Efficacy and safety of NNC0487-0111s.c once weekly in participants with obesity who have reached target dose during run-in period (AMAZE12).
2025-523804-62-00Obesity
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Belgium, Germany, Bulgaria, France, Spain, Denmark, Italy, Netherlands
27/04/2026
Phase I
A research study looking into blood levels of the medicine NNC0487 0111 in the body and how well it is tolerated in people with reduced liver function and normal liver function
2025-521647-20-00hepatic impairment
Novo Nordisk A/S
Not possible to specify
Slovakia
27/04/2026
Phase I
A research study investigating the effect of NNC0497-0040 in healthy participants, participants with overweight or obesity, and participants with type 1 diabetes with overweight or obesity.
2025-523978-16-00Type I diabetes
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Germany
23/04/2026
Phase I
A research study to compare blood levels of cagrilintide after multiple doses of different versions of cagrilintide in adults with overweight or obesity
2025-521384-12-00obesity
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Germany
21/04/2026
Phase II
Protocol Title: Efficacy and safety of once-weekly subcutaneous NNC0662-0419 in participants with type 2 diabetes – a dose-finding study
2025-523260-20-00type 2 diabetes
Novo Nordisk A/S
Hormonal diseases
Spain, Hungary, Portugal, Poland, Slovakia, Croatia
21/04/2026
Phase I
A research study to evaluate the safety of NNC1679-0001 when given to healthy participants and participants with T2DM
2025-523304-68-00Healthy participants and participants with type 2 diabetes
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Austria
19/04/2026
Phase III
Efficacy and safety of NNC0487-0111 compared to placebo on morbidity and mortality in people with heart failure with preserved or mildly reduced ejection fraction and obesity (HF-POLARIS).
2025-523717-29-00HFpEF or HFmrEF and obesity
Novo Nordisk A/S
Cardiovascular Diseases
Denmark, Greece, Bulgaria, Italy, Netherlands, Spain, Poland, Czechia, Germany, France
17/04/2026
Phase III
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and knee osteoarthritis (AMAZE 5)
2024-520444-42-00Overweight or obesity, and knee osteoarthritis
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Italy, Greece, Spain, Bulgaria, Denmark, Poland
07/04/2026
Rows per page Showing 1–25 of 42
1 2 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 21 September 2026. https://priyalifescience.com/clinical-trials-europe

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.